Verastem, Inc. (0LOV.L)
USD 4.46
(-3.44%)
USD 4.46
(-3.44%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -92.08 Million USD | -26.25% |
| 2022 | -72.93 Million USD | -18.77% |
| 2021 | -61.4 Million USD | -24.41% |
| 2020 | -49.36 Million USD | 62.7% |
| 2019 | -132.34 Million USD | -39.63% |
| 2018 | -94.78 Million USD | -39.79% |
| 2017 | -67.8 Million USD | -83.24% |
| 2016 | -37 Million USD | 36.42% |
| 2015 | -58.19 Million USD | -8.57% |
| 2014 | -53.6 Million USD | -29.48% |
| 2013 | -41.4 Million USD | -28.46% |
| 2012 | -32.23 Million USD | -135.29% |
| 2011 | -13.69 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -28.05 Million USD | 9.89% |
| 2024 Q2 | -18.27 Million USD | 34.86% |
| 2023 FY | -92.08 Million USD | -26.25% |
| 2023 Q3 | -21.3 Million USD | -5.01% |
| 2023 Q4 | -31.13 Million USD | -46.13% |
| 2023 Q2 | -20.29 Million USD | -4.9% |
| 2023 Q1 | -19.34 Million USD | -14.83% |
| 2022 Q1 | -16.98 Million USD | -2.84% |
| 2022 FY | -72.93 Million USD | -18.77% |
| 2022 Q4 | -16.84 Million USD | 4.87% |
| 2022 Q3 | -17.7 Million USD | 17.26% |
| 2022 Q2 | -21.4 Million USD | -26.04% |
| 2021 Q4 | -16.51 Million USD | -11.22% |
| 2021 Q3 | -14.84 Million USD | 6.89% |
| 2021 Q2 | -15.94 Million USD | -13.01% |
| 2021 Q1 | -14.1 Million USD | 15.79% |
| 2021 FY | -61.4 Million USD | -24.41% |
| 2020 Q3 | 15.01 Million USD | 170.62% |
| 2020 FY | -49.36 Million USD | 62.7% |
| 2020 Q1 | -26.35 Million USD | 20.82% |
| 2020 Q2 | -21.26 Million USD | 19.33% |
| 2020 Q4 | -16.75 Million USD | -211.57% |
| 2019 FY | -132.34 Million USD | -39.63% |
| 2019 Q4 | -33.29 Million USD | -27.54% |
| 2019 Q3 | -26.1 Million USD | 31.81% |
| 2019 Q2 | -38.27 Million USD | -10.4% |
| 2019 Q1 | -34.67 Million USD | -1.2% |
| 2018 Q3 | -21.56 Million USD | -18.55% |
| 2018 Q4 | -34.25 Million USD | -58.83% |
| 2018 Q2 | -18.19 Million USD | 12.36% |
| 2018 Q1 | -20.76 Million USD | -15.01% |
| 2018 FY | -94.78 Million USD | -39.79% |
| 2017 FY | -67.8 Million USD | -83.24% |
| 2017 Q1 | -13.14 Million USD | -11.42% |
| 2017 Q4 | -18.05 Million USD | 21.98% |
| 2017 Q3 | -23.13 Million USD | -71.81% |
| 2017 Q2 | -13.46 Million USD | -2.43% |
| 2016 Q2 | -8.7 Million USD | -3.26% |
| 2016 Q3 | -8.05 Million USD | 7.46% |
| 2016 Q1 | -8.43 Million USD | 29.49% |
| 2016 FY | -37 Million USD | 36.42% |
| 2016 Q4 | -11.8 Million USD | -46.42% |
| 2015 FY | -58.19 Million USD | -8.57% |
| 2015 Q4 | -11.96 Million USD | 23.0% |
| 2015 Q3 | -15.53 Million USD | -0.47% |
| 2015 Q2 | -15.46 Million USD | -1.44% |
| 2015 Q1 | -15.24 Million USD | -8.89% |
| 2014 FY | -53.6 Million USD | -29.48% |
| 2014 Q3 | -13.38 Million USD | -2.3% |
| 2014 Q2 | -13.08 Million USD | 0.36% |
| 2014 Q1 | -13.13 Million USD | -15.28% |
| 2014 Q4 | -13.99 Million USD | -4.56% |
| 2013 FY | -41.4 Million USD | -28.46% |
| 2013 Q1 | -9.08 Million USD | -13.85% |
| 2013 Q2 | -10.28 Million USD | -13.25% |
| 2013 Q3 | -10.64 Million USD | -3.5% |
| 2013 Q4 | -11.39 Million USD | -7.04% |
| 2012 Q2 | -6.89 Million USD | 0.46% |
| 2012 FY | -32.23 Million USD | -135.29% |
| 2012 Q1 | -6.92 Million USD | -15.08% |
| 2012 Q3 | -10.43 Million USD | -51.25% |
| 2012 Q4 | -7.97 Million USD | 23.53% |
| 2011 Q4 | -6.02 Million USD | -48.75% |
| 2011 Q3 | -4.04 Million USD | -62.86% |
| 2011 Q2 | -2.48 Million USD | -116.84% |
| 2011 Q1 | -1.14 Million USD | 0.0% |
| 2011 FY | -13.69 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -169.18 Million USD | 45.571% |
| Dynavax Technologies Corporation | -37.02 Million USD | -148.687% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -1647.656% |
| Perrigo Company plc | 151.9 Million USD | 160.621% |
| Illumina, Inc. | -1.06 Billion USD | 91.386% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 101.343% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 80.006% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 99.346% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 104.658% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 16.753% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 102.275% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -106.157% |
| Waters Corporation | 817.67 Million USD | 111.262% |
| Biogen Inc. | 1.29 Billion USD | 107.101% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 66.393% |
| Evolus, Inc. | -49.23 Million USD | -87.037% |
| Adicet Bio, Inc. | -152.03 Million USD | 39.434% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 24.208% |
| bluebird bio, Inc. | -244.26 Million USD | 62.301% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 40.806% |
| FibroGen, Inc. | -281.81 Million USD | 67.325% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 106.821% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -104.28% |
| Homology Medicines, Inc. | -48.25 Million USD | -90.828% |
| Geron Corporation | -193.94 Million USD | 52.52% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 67.366% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -25.295% |
| Myriad Genetics, Inc. | -123.7 Million USD | 25.559% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 8.671% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 82.13% |
| Zoetis Inc. | 3.06 Billion USD | 103.0% |
| Abeona Therapeutics Inc. | -48.2 Million USD | -91.046% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 108.469% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 147.358% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 102.138% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -135.19% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 73.968% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 66.637% |
| Nektar Therapeutics | -137.42 Million USD | 32.993% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 60.279% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 5.416% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 65.618% |
| OPKO Health, Inc. | -157.02 Million USD | 41.356% |
| Exelixis, Inc. | 170.88 Million USD | 153.887% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 136.701% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 185.834% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -65.155% |
| uniQure N.V. | -282.87 Million USD | 67.447% |
| Imunon, Inc. | -21.03 Million USD | -337.861% |
| Blueprint Medicines Corporation | -486.27 Million USD | 81.063% |
| Insmed Incorporated | -709.62 Million USD | 87.024% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 127.278% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 76.478% |
| TG Therapeutics, Inc. | 20.63 Million USD | 546.295% |
| Incyte Corporation | 620.52 Million USD | 114.84% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 87.323% |